 |
 |
 |
Our commitment to
excellence.
By radically changing the standard of care, Asthmatx will become the leading provider of therapeutic medical devices for patients who suffer from asthma.
FAQ
What is the AIR2 Trial?
The AIR2 Trial: The objective of this randomized, double blind, sham-controlled study is to evaluate the safety and efficacy of Bronchial Thermoplasty with the Alair® System in a population of subjects with severe asthma who are still symptomatic despite being managed on conventional therapy.
Wilson S, Cox G, Miller J, et al, Global Assessment After Bronchial Thermoplasty: the Patient’s Perspective, J of Outcomes Res 2006;10:37-46
Global Assessment After Bronchial Thermoplasty: the Patient’s Perspective
Wilson SR, Cox G, Miller JD, Lam S
Abstract
Reported clinical benefits of bronchial thermoplasty (BT) in 16 subjects with asthma (reduced airway hyperresponsiveness, improved peak flow, increased symptom-free days) motivated an assessment of quality of life changes and patient satisfaction with the procedure. A 13-item questionnaire was administered 2 months after the last patient completed the 12-month follow-up (i.e. 14–36 months post-BT). Patients reported an increased ability to carry out activities (n = 14), increased tolerance to allergens (n = 13) and increased tolerance for physical exertion (n = 14). All patients indicated that they would ‘probably’/’definitely’ undergo the procedure again and would recommend it. These results suggest that BT may have a positive impact on longterm quality of life in asthma patients.
CAUTION: The Alair® System is an Investigational device.
It is limited by United States law to investigational use. To be used by Qualified Investigators only.
Alair, Asthmatx, and It's about breathing are trademarks or registered trademarks of Asthmatx, Inc.
Copyright © 2006, Asthmatx Inc. All Rights Reserved.
Last Updated: August 22, 2007
